GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
Global Blood Therapeutics (GBT) will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 11:45 a.m. ET. This event will be broadcast live on GBT's website, with a replay available for one month afterward. GBT is focused on innovative treatments for sickle cell disease, boasting Oxbryta® as the first FDA-approved medication targeting hemoglobin polymerization. The company is also developing additional treatments, including inclacumab and GBT021601, to improve patient care.
- GBT is participating in a prominent conference, enhancing visibility among investors.
- The company is advancing its pipeline with promising treatments for sickle cell disease.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 11:45 a.m. ET.
The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next-generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
What event is GBT participating in on December 1, 2021?
How can I watch GBT's fireside chat?
What is the significance of GBT's Oxbryta®?
What are GBT's future developments in sickle cell treatments?
